33 results about "Fas ligand" patented technology

Methods for sustained delivery of biologically active proteins or peptides to mammals are disclosed. Specific types of immune-privileged allogeneic or xenogenic donor cells that are naturally immune privileged are genetically modified in vitro to express or secrete the proteins or peptides. The genetically modified donor cells are subsequently implanted into host mammals and utilized for sustained delivery of biologically active proteins or peptides in vivo. The donor cells so utilized are those that inherently possess immune privilege due at least partly to the expression of Fas ligand. Methods for cell isolation, purification, tissue culture expansion, cryopreservation, gene transfer, transgene and Fas ligand expression, cell implantation, and measurement of immune responses of host animals are described.

Novel humanized immunoglobulins and active fragments thereof which are specifically reactive to Fas ligand are provided, and a site on Fas ligand which is important to inhibit apoptosis induced by the Fas-Fas ligand interaction against Fas-expressing cells is demonstrated. The novel humanized immunoglobulins and active fragments thereof which are specifically reactive to Fas ligand are prepared from hybridomas which produce monoclonal antibodies specifically reactive to Fas ligand, via recombinant DNA techniques. The humanized immunoglobulins can inhibit the physiological reactions between Fas ligand and Fas such as apoptosis. Further, identification of the site which is on Fas ligand and responsible for apoptosis induction allows creation of recombinant proteins or peptides which are specifically reactive to the amino acids within the site so as to inhibit apoptosis, and to find new therapeutic or diagnostic agents.

The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.

The invention provides monoclonal antibodies, which specifically react with a Fas ligand, or active fragments thereof, a production process of the monoclonal antibodies, which specifically react with a Fas ligand, hybridomas separately producing a monoclonal antibody, which specifically reacts with a Fas ligand present on a cell surface, a method of detecting a Fas ligand in a solution, and a kit for use in detecting a Fas ligand, comprising plurality of monoclonal antibodies against Fas ligand in combination.

Provided are fusion proteins comprising a first domain and a second domain, wherein the first domain comprises a polypeptide that binds to and triggers PD-1 and the second domain comprises a polypeptide that binds to and triggers a TRAIL receptor or Fas. In some embodiments, the polypeptide that binds to and triggers PD-1 comprises at least a portion of the extracellular domain of PD-L1 or PD-L2 and the second domain comprises at least a portion of the extracellular domain of TRAIL or Fas ligand. Also provided are methods for treating autoimmune, alloimmune or inflammatory diseases, and methods for treating cancer, using the fusion proteins.

Methods and compositions are disclosed for inhibiting, deterring or preventing apoptosis of cardiac myocytes, transplanted stem cells, vascular stem cells, and vascular smooth muscle cells by means of expressing or synthesizing clusterin. Also disclosed are methods and compositions for producing recombinant clusterin, or its biologically active peptides, and for induction of clusterin-associated lipoproteins or enzymes for deterring or preventing inflammatory injury and apoptosis induced by oxLDL, oxysterols, cytokines, and Fas Ligand. Also disclosed is an induction method and composition for enhancing expression of ALDH and ALDH-associated enzymes or co-factors to prevent cytotoxicity or detoxification. Therapeutic methods providing new expression or overexpression of clusterin in vascular or cardiac tissue are expected to inhibit the formation of atherosclerotic lesions, stabilize existing atherosclerotic plaques, and repair failing or damaged cardiac tissue.

Novel bifunctional peptides useful in the treatment and/or diagnosis of EAE or MS. The peptides have a first peptide portion derived from an epitope of myelin proteolipid protein, myelin oligodendrocyte glycoprotein, or oligodendrocyte-specific peptide and a second peptide portion derived from CD11a (LFA-1 alpha subunit), CD18 (LFA-1 beta subunit), CD154 (CD40L), Fas-Ligand, or CTLA4. The carboxy and/or amino termini of the bifunctional peptides may be modified.

This disclosure relates in general to a stem cell treatment. This disclosure further relates to a stem cell treatment using a composition comprising stem cells having highly expressed Fas-L. This disclosure further relates to a stem cell treatment of multiple myeloma. This disclosure also relates to a composition comprising stem cells having highly expressed Fas-L. This disclosure also relates to preparation of a composition comprising stem cell having highly expressed Fas-L. This disclosure also relates to preparation of a composition comprising stem cells having highly expressed Fas-L by using a salicylate. An example of salicylate may be aspirin. This disclosure further relates to a stem cell treatment of multiple myeloma. This disclosure also relates to a stem cell treatment of an inflammatory disease and/or autoimmune disease.

The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the tumour necrosis factor (TNF) superfamily such as TNF-a, Lymphotoxin-a (LT-a), TNFRI, TNFRII, OX40, BAFF, NGFR, Fas Ligand or chimeric molecules thereof comprising at least a portion of the protein molecule, such as TNF-a-Fc, LT-a-Fc, TNFRI-Fc, TNFRII-Fc, OX40-Fc, BAFF-Fc, NGFR-Fc, Fas Ligand-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.

PCT No. PCT/JP96/03089 Sec. 371 Date Apr. 27, 1998 Sec. 102(e) Date Apr. 27, 1998 PCT Filed Oct. 24, 1996 PCT Pub. No. WO97/15326 PCT Pub. Date May 1, 1997The invention provides therapeutic agents for hepatitis, comprising an antibody against a human Fas ligand, or an active fragment thereof as an active ingredient. The therapeutic agents for hepatitis according to the invention are particularly effective for the treatment of hepatitis caused by the death of hepatocytes due to apoptosis among many kinds of hepatitis.

The present invention provides structures of small molecules capable of modulating apoptotic cell death. More specifically, the structures relate to the structures of apoptotic active sites of mammalian alpha-fetoprotein (AFP) and albumin. Peptides mimicking the active site contain two sequences, Arg-Gly-Asp and Asp-X-X-Asp, wherein X means any amino acid. These sequences are needed in the same molecule for causing a wide range of biological activities. The peptides can be utilized to suppress apoptotic pathways by inhibiting the cytochrome c-mediated caspaseactivation. Thus, the peptides can be used to inhibit effects of apoptosis induced by oxidative stress, drugs, cytokines, Fas-ligand, alpha-fetoprotein, used to prevent apoptosis in culturing cells, in organ transplantation, in immunological autoimmune disorders and immunodeficiency syndrom induced by viral infection, or to diminish side cytotoxic effects after chemotherapy and radiation therapy.

Tumor target and recombined human Fas ligand fusion protein and a preparation method thereof relate to a gene and provide construction, expression and purification of tumor target specific binding peptide and recombined human Fas ligand fusion protein gene as well as in vitro and vivo biology activity identification method. Fas ligand cDNA complete sequence is searched from GenBank, Arg-Lys-Arg is added by Linker(YNFPQQMLKCFC) at terminal N of the complete sequence to obtain original gene sequence for coding the tumor target specific binding peptide and recombined human Fas ligand fusion protein; nucleotide sequence of the tumor target specific binding peptide and recombined human Fas ligand fusion protein is modified according to degeneracy of codon and codon preference principle of colon bacillus; the modified fusion protein sequence is divided into twelve long primer segments, and BamH I and Xho I enzyme restriction sites are introduced; and the fusion protein gene is obtained by PCR reaction.

Provided by this invention is a fusion protein which is capable of binding to Fas, and which comprises a peptide comprising at least a part of the amino acid sequence of Fas ligand, a peptide having oligomerization ability, and a peptide which increases recombinant protein production. Also provided are a method for using the FLAG-like peptide for the purpose of increasing the production of the recombinant protein, and a method for using the FLAG-like peptide for the purpose of increasing the biological activity of the fusion protein of the leucine zipper and the transmembrane protein.

The present invention is directed to a method of modulating inflammation within an immune privileged site in an animal by introducing an effective amount of a Fas ligand fragment comprising the extracellular domain of a full length Fas ligand, a derivative thereof, or a nucleic acid encoding the Fas ligand fragment, behind the blood-tissue barrier of the immune privileged site. In one embodiment the invention pertains to methods of modulating inflammation in the central nervous system generally, at specific lesions in the central nervous system, anterior chamber of the eye, testis, placenta and other immune privileged sites in a mammal. The FasL fragments used in the method of the present invention contain the extracellular domain of FasL and are soluble. The method of the present invention comprises the step of directly administering the FasL fragment, or derivative thereof, or a composition comprising the FasL fragment, or derivative thereof, behind the blood-tissue barrier of the immune privileged site.

The present invention discloses a human antibody that specifically binds to human Fas ligand (hFasL), and preferably the human antibody is a recombinant human antibody. These antibodies have high affinity for hFasL, have a low off-rate for hFasL dissociation and neutralize Fas ligand activity in vivo and in vitro. Antibodies of the invention may be full-length antibodies or antigen-binding portions thereof. Antibodies or antigen binding portions of the invention may be used to neutralize Fas ligand activity, for example, in a patient suffering from a disorder in which hFas ligand activity is deleterious. Nucleic acids, vectors and host cells for expressing the recombinant anti-hFasL human antibody as well as methods for synthesizing the recombinant human antibody are also encompassed by the present invention.

Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.

The present invention provides compositions and devices that release (a) a nitric oxide (NO) donor and/or NO, and (b) an agent that aggregates and/or trimerizes the Fas receptor, such as but not limited to a Fas-ligand (FasL). In certain embodiments, the invention includes a stent that elutes (a) a NO donor and/or NO, and (b) FasL. In other embodiments, the invention includes methods of treating a condition, such as intimal hyperplasia, in a subject by administering a stent that releases (a) a NO donor and/or NO, and (b) FasL.

The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells thereby inhibiting VEGF activation of VEGF receptors and inducing apoptosis in the tumor cells. Fusion proteins of the present invention are useful for inducing apoptosis and cytotoxic effects in cells, treating cancer and diseases or disorders related to unregulated angiogenesis and/or vasculogenesis. Thus, this invention further provides methods for treating angiogenesis related diseases using the fusion proteins, polynucleotides encoding the fusion proteins, vectors containing the polynucleotides, pharmaceutical compositions and kits containing the fusion proteins or the polynucleotides encoding the fusion proteins.

The invention provides a death ligand antibody coupled polyethylene glycol modified lipid nano drug delivery system, which is delivered by preparing polyethylene glycol (PEG) modified and death ligand (Fas ligand) antibody coupled lipid nanoparticles Combined with the experimental animal model of ischemic brain injury, the pharmacodynamic indicators of the brain-targeted nano-drug delivery system coupled with Fas ligand antibody were evaluated from the whole animal level, which proved its good brain-targeting and brain-deficient drug delivery system. Targeting of the blood area. From the reduction of infarct size and the improvement of animal nerve function damage and other indicators, it is proved that the drug delivery system can reduce the drug dose and improve the efficacy of the drug, so as to provide a more efficient and low-toxic drug delivery system for the clinical treatment of ischemic stroke. .